全部新闻

讨论、会议及分享

网络研讨会和播客

新闻稿

Intrasense presence at ECR (European Congress of Radiology) from February 26 to March 2, 2025 in Vienna

3 2 月 2025

Montpellier, France, February 3, 2025. Intrasense (ISIN: FR0011179886 – Mnémo : ALINS), French expert in medical imaging solutions enhanced by AI assisting and securing diagnosis, decision-making and therapeutic follow-up, announces its participation in the European Congress of Radiology (ECR) 2025, which will take place between February 26 and March 2 in Vienna (Austria).

发现更多

Financial calendar 2025

27 1 月 2025

Intrasense (ISIN: FR0011179886), French expert in medical imaging solutions to assist and secure diagnosis, decision-making and therapeutic follow-up, announces the publication of its financial calendar for fiscal year 2025.

发现更多

Intrasense announces the CE marking of Liflow®’s new version enhanced by AI dedicated to the liver

16 12 月 2024

Intrasense (FR0011179886 - ALINS), medical imaging software solutions expert and developer of Myrian® et Liflow®, is proud to announce that the Lilfow® solution obtained the CE certification under MDR1, integrating a new AI algorithm for the detection of focal liver lesions developed in collaboration with Guerbet (trade name: DUOnco™ Liver). This new version is being deployed on clinical sites.

发现更多

Guerbet, Intrasense, Gustave Roussy and the University Hospital of Angers receive a €5.9M financing from Bpifrance for Liflow®, innovative solution dedicated to oncology imaging

3 12 月 2024

Guerbet (FR0000032526 GBT) worldwide expert in contrast agents and medical imaging solutions, Intrasense (FR0011179886 - ALINS), expert in medical imaging software solutions and developer of Myrian® and Liflow®, Gustave Roussy, 1st cancerology centre in France and Europe and Angers University Hospital (« Partners ») announce they have received €5.9M in funding from Bpifrance’s “Innovation in Medical Imaging” call for proposals. The Oncology Assistant (trade name: Liflow®) project, carried by the four Partners uses AI (artificial intelligence) to facilitate and optimize the follow-up of cancer patients. It benefits from public funding to ensure its future development.

发现更多

Intrasense announces the CE marking of Myrian 2.13, enriched by the new version of Guerbet’s prostate AI

20 11 月 2024

Intrasense (FR0011179886 - ALINS), spécialiste des solutions logicielles d’imagerie médicale et concepteur de Myrian® et Liflow®, est fier d’annoncer que la plateforme Myrian® 2.13 a obtenu le certificat CE sous MDR1, intégrant une nouvelle version majeure de l’IA prostate développée par Guerbet, l’IA Veolity® LungCAD développée par MeVis Medical Solutions AG et l’IA Icobrain™ développée par Icometrix.

发现更多

我们的大会

博客或新闻

想获得最新的消息吗

访问